– Dr. Adam Kaplin
Reveals Pioneering Neuropsychiatric
Advancements at the University of
Louisville –
BALTIMORE, Nov. 21,
2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative
pre-clinical-stage pharmaceutical company, today revealed
groundbreaking insights into the cognitively enhancing effects of
MIRA1a in normal mice during a presentation at the University of Louisville's Christine Lee Brown
Envirome Institute's Grand Rounds from Dr. Adam Kaplin, MD, Ph.D., President and Chief
Scientific Officer of MIRA Pharmaceuticals and Adjunct Faculty
member at the Johns Hopkins School of
Medicine.
Dr. Kaplin's presentation covered his research
on psychotropic drug development, specifically examining the
contrasting properties of THC and MIRA1a, a novel, cutting-edge THC
analog.
Key Findings from Dr. Kaplin's
Presentation:
- Overcoming Biphasic Response: While THC exhibited
limitations with a biphasic response, being therapeutic at low
doses but toxic at high doses, MIRA1a showcased unparalleled
stability, even at high doses, without any toxic side effects.
- Unprecedented Cognitive
Boost: MIRA1a demonstrated a doubling of the
performance of normal adult mice in learning and memory tests,
showcasing MIRA1a's potential to elevate cognitive abilities beyond
normal thresholds.
"The revelation of MIRA1a's dramatic cognitive enhancement
potential acutely after even a single dose marks a seismic shift in
neuropsychiatric research," said Dr. Kaplin, MD, Ph.D., President
and Chief Scientific Officer of MIRA. "This discovery positions
MIRA Pharmaceuticals at the forefront of transformative
developments in psychotropic drug innovation."
Erez Aminov, Chief Executive
Officer of MIRA, added: "At MIRA Pharmaceuticals, we are committed
to seizing industry-defining opportunities. The immense market
potential lies ahead as we focus on anxiety and neuropathic pain
within the traditional $90+ billion traditional neurological
markets1."
Implications and Future Prospects:
Dr. Kaplin's
findings propose a revolutionary approach to cognitive impairment
treatment, particularly in early dementia. MIRA1a's consistent
therapeutic effects, even at high doses, positions it as a
promising candidate for the treatment of neuropsychiatric diseases
such as dementia.
Investors and stakeholders are encouraged to explore the
profound implications of this research, solidifying
MIRA Pharmaceuticals as a trailblazer in the evolving
landscape of psychotropic drug development.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company developing an
unscheduled novel synthetic THC analog. This novel compound is
currently under investigation for treating adult patients suffering
from anxiety and cognitive decline, often associated with
early-stage dementia. MIRA1a, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders. Based on
pre-clinical and animal studies conducted by the Company, the
Company believes that MIRA1a may enhance the therapeutic potential
for treating anxiety, cognitive decline, and neuropathic pain
without the side effects of plant-based THC. Furthermore, the
Company's studies indicate that MIRA1a may counteract the adverse
cognitive effects often seen with THC, thereby potentially
unmasking previously unseen positive therapeutic effects, such as
cognitive performance enhancement.
The U.S. Drug Enforcement Administration (DEA)'s scientific
review of MIRA1a concluded that MIRA1a would not be considered a
controlled substance or listed chemical under the Controlled
Substances Act (CSA) and its governing regulations.
Additional information about the Company is available
at: www.mirapharmaceuticals.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements about
MIRA Pharmaceuticals, Inc. ("MIRA," "we," "us," or "our"). In some
cases, you can identify forward-looking statements by terminology
such as "anticipate,' "believe," "contemplate," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will" or
"would," or the negative of these terms or other comparable
terminology. These forward-looking statements are subject to
numerous risks and uncertainties, many of which are beyond our
control, including risks and uncertainties regarding our ability to
develop and obtain regulatory approval for our product candidate,
MIRA1a. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause our
actual results, levels of activity, performance or achievements of
and those of our industry to be materially different from any
future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. Some of
these risks and uncertainties are identified in our Registration
Statement on Form S-1 filed with the SEC (File No. 333-273024) and
in our other filings with the SEC, which are available
at www.sec.gov. You should not place undue reliance on any
forward-looking statement. We undertake no obligation to update or
revise publicly any of the forward-looking statements after the
date hereof to conform the statements to actual results or changed
expectations except as required by law.
General Note
This press release discusses a product candidate that is in
early stage pre-clinical development and has not yet been approved
for marketing by the U.S. Food and Drug Administration. No
representation is made as to the safety or effectiveness of this
product candidate for the uses for which it is being studied. There
is no assurance that the product candidate will proceed through
development or will receive FDA approval for marketing.
1 Source: IQVIA Analysis, IQVIA Global Uses of
Medicine Report – 2022 and 2023, Mira Analysis
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-announces-paradigm-shift-in-cognitive-enhancement-with-mira1a-301994921.html
SOURCE MIRA Pharmaceuticals, Inc.